Dupixent Lawsuit for T-Cell Lymphoma

Dupixent lawsuits are now moving forward in federal court for patients who allege the drug caused, accelerated, or unmasked cutaneous T-cell lymphoma and related T-cell lymphomas.

On June 4, 2026, the Judicial Panel on Multidistrict Litigation centralized the federal Dupixent cases in MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi.

Dupixent, also known as dupilumab, is a biologic medication used to treat atopic dermatitis, asthma, COPD, and a host of other inflammatory conditions. For many patients, Dupixent has provided real relief where other treatments failed. But for some patients, the story has been very different and not one they could have expected.

Dupixent lawsuits allege that Regeneron and Sanofi failed to warn doctors and patients that cutaneous T-cell lymphoma (CTCL) can mimic eczema so that Dupixent masks, accelerates, or delays diagnosis of an underlying lymphoma. Our lawsuits contend that patients with adult-onset, atypical, or treatment-resistant dermatitis should have been warned to rule out lymphoma before starting Dupixent and, more importantly, to stop and investigate if symptoms changed during treatment.

Our lawyers are reviewing cases involving Dupixent users later diagnosed with CTCL, peripheral T-cell lymphoma, mycosis fungoides, or Sézary syndrome, especially where the patient developed swollen lymph nodes, worsening skin disease, systemic symptoms, chemotherapy, radiation, photopheresis, or stem cell transplant after treatment.

Page written by Ronald V. Miller Jr. This page is for patients and families trying to understand the connection between Dupixent and T-cell lymphoma, the federal MDL, and potential civil claims. We updated this page on September 15, 2026.

Call us today at 800-553-8082 or get a free online consultation if you or a loved one developed T-cell lymphoma after taking Dupixent.

September 2026 Update: Dupixent MDL Now Has a Proposed Litigation Schedule

The Dupixent lymphoma litigation is starting to take shape. Until now, there really was not much of a schedule. That changed on September 10, 2026, when the plaintiffs and defendants filed a joint management report laying out how they think this litigation should proceed. The judge still has to approve the schedule, so these are proposed dates. But for the first time, we have a pretty good picture of what the next year and a half of the Dupixent litigation may look like.

The big issue comes first: can Dupixent cause or accelerate cutaneous T-cell lymphoma? Lawyers call this general causation. Before the court spends years working through individual cases and preparing bellwether trials, the defendants want the judge to decide whether plaintiffs have reliable scientific evidence showing that Dupixent is capable of causing or worsening CTCL.

That makes this first phase extremely important. We believe the scientific evidence supporting a relationship between Dupixent and CTCL is incredibly strong, which is why attorneys like us are so high on these cases. Of course, Sanofi and Regeneron say other factors explain the association, including the underlying skin conditions Dupixent is used to treat and the difficulty doctors have distinguishing early CTCL from severe atopic dermatitis. This disagreement cuts to the core of this litigation.

Proposed Dupixent MDL Schedule

Proposed Date	What Happens	Why It Matters
November 16, 2026	The current stay on general causation discovery would end. Defendants would also produce the complete Dupixent regulatory file.	This is when the real discovery fight begins over what Sanofi and Regeneron knew about CTCL, what they studied, what they told regulators, and what their internal safety work showed.
December 18, 2026	Current plaintiffs would begin providing short Plaintiff Profile Forms, medical provider information, dates of Dupixent use, medical authorizations, and available medical records, assuming the court enters the proposed order on time.	The MDL is beginning to collect basic information about the people bringing these lawsuits, but full Plaintiff Fact Sheets are not expected until the later phase of the litigation.
January 15, 2027	The parties would submit a schedule for discovery involving the separate Dupixent medical monitoring class action.	That case involves Dupixent users who have not been diagnosed with lymphoma but claim they need ongoing medical surveillance because of an increased CTCL risk.
May 7, 2027	Defendants would certify that their Phase I document production is substantially complete.	Plaintiffs should have most of the major company documents needed to develop their scientific and regulatory case.
October 8, 2027	Phase I fact discovery would close.	The focus then shifts heavily toward the experts who will testify about whether Dupixent can cause or worsen CTCL.
November 8, 2027	Plaintiffs would serve their general causation expert reports.	This is where plaintiffs formally lay out the expert science supporting the claim that Dupixent can cause or accelerate CTCL.
December 8, 2027	Defendants would serve their general causation expert reports.	Sanofi and Regeneron will present their scientific explanation for why Dupixent does not cause CTCL.
February 28, 2028	General causation expert depositions would be completed. The parties would also propose the next phase of discovery and a process that could eventually lead to bellwether case selection.	This tells us something important about timing. Under this proposal, the MDL is not heading toward Dupixent bellwether trials anytime soon.
March 23, 2028	Daubert motions and summary judgment motions concerning general causation would be filed.	This may be the most important motion practice in the entire litigation. Defendants will try to exclude plaintiffs’ causation experts and potentially knock out the CTCL claims before trials begin.
May 19, 2028	Final reply briefs on general causation would be due.	After briefing is complete, the court can decide whether the plaintiffs’ general causation evidence is strong enough for the cases to move forward.

So What Does This Mean If You Have a Dupixent CTCL Claim?

It means this litigation will start to move forward. Can we expect a settlement soon? That would be extremely unlikely. It is a rare MDL where you see an early settlement. Instead, you see defense lawyers eagerly dragging the litigation out to pressure the victims while hoping to get out on motion long before we ever see a trial date. The proposed schedule spends most of the next eighteen months on the kind of discovery we do in the MDL. If you are not in the mass tort world, it seems like a long, drawn-out ordeal. Which it is. But this is very typical and, if this schedule holds, it is the fastest path we could hope for.

Assuming we win the causation fight, and we think we will, the litigation will move into a much more case-specific phase where we stop looking at the big picture and start looking at selected individual cases. The idea is that you get cases ready for bellwether trial to test how juries respond to these claims.

If plaintiffs lose the general causation fight, the consequences could be much more serious. Defendants are clearly trying to make causation a threshold issue. If the court excludes the key plaintiff experts or finds that the scientific evidence is legally insufficient, some or potentially many CTCL cases could be dismissed before ever reaching a jury.

There is another important point here. This is still not a Dupixent class action for people who developed CTCL. Each injured plaintiff keeps an individual lawsuit. Your diagnosis, how long you used Dupixent, when your symptoms began, your biopsy history, how advanced the lymphoma became, your treatment, and your prognosis all remain important. Those differences should also matter tremendously if this litigation eventually reaches a global settlement.

We like the MDL structure for that reason. Plaintiffs can work together on the expensive common fight over the science and what the drug companies knew while still preserving the individual value of each case. A patient who developed advanced CTCL and required chemotherapy, radiation, a stem cell transplant, or who died from the disease has a very different damages case from someone with a less severe disease course. Any eventual Dupixent settlement should reflect those differences.

Who May Qualify for a Lawsuit?

Our attorneys are reviewing cases from patients who received Dupixent and were later diagnosed with T-cell lymphoma. You do not need to know whether the drug caused the lymphoma before calling. The first step is a medical record review, including dermatology notes, biopsy reports, pathology, oncology records, prescription history, and treatment timeline.

Who Probably Does Not Have a Strong Case?

You may have a hard time finding a lawyer for a Dupixent case if the patient took the drug but was never diagnosed with CTCL, PTCL, mycosis fungoides, Sézary syndrome, or another T-cell lymphoma. Most of the lawsuits will be CTCL cases. A temporary rash, eye irritation, conjunctivitis, a typical eczema flare, or a short-term side effect are not the injuries our lawyers are focused on in this litigation.

A case may also be difficult if the CTCL diagnosis clearly predated treatment, if the patient took only one or two doses with no meaningful timing connection, or if the records show no worsening, delayed diagnosis, systemic symptoms, lymph node involvement, or treatment burden after use.

The key records are the treatment timeline, dermatology notes, biopsy history, pathology reports, oncology records, and the clinical course before and after the drug.

What Is Cutaneous T-Cell Lymphoma?

Cutaneous T-cell lymphoma is a cancer of the immune system involving malignant T cells that migrate to the skin. In its early stages, CTCL often looks almost indistinguishable from eczema, psoriasis, or other chronic inflammatory skin conditions. It behaves like a wolf in sheep’s clothing, presenting as ordinary rashes, plaques, itching, or redness that flare up and fade away, giving the impression of a manageable skin disorder rather than a developing cancer.

That disguise is one of the things that makes CTCL so dangerous. The disease can hide in plain sight for years. Patients have biopsies that come back inconclusive and symptoms that mimic benign skin problems. Like a slow-burning fire behind a wall, CTCL may continue progressing quietly until it finally reveals itself, often at a more advanced stage that is far harder to treat.

The most common forms of CTCL are mycosis fungoides and Sézary syndrome. Both are serious, life-altering conditions that often require lifelong treatment. In advanced cases, they can be fatal.

Why CTCL Gets Misdiagnosed as Eczema

One of the problems with CTCL, and a big issue in these lawsuits, is that early CTCL can look an awful lot like eczema. Not vaguely like eczema. Sometimes enough like eczema that an experienced dermatologist can reasonably look at the patient, look at the symptoms, and think that eczema is exactly what he or she is treating.

The overlap is pretty remarkable. Both conditions can cause:

Red, inflamed patches
Itchy, scaly skin
Lichenification, meaning thickened and leathery skin
Fissuring and cracking
Symptoms that get better for a while and then come back

Mycosis fungoides, the most common form of CTCL, often starts with flat, scaly patches that look like dermatitis. Topical steroids may even make those patches look better for a while.

Then there is the biopsy problem. A biopsy does not always immediately solve the mystery. Early CTCL can produce an inconclusive biopsy, which means the patient may leave the dermatologist’s office with basically the same working diagnosis he or she walked in with: stubborn eczema.

This is where Dupixent becomes important to these lawsuits. A patient is treated for what everyone believes is eczema. Dupixent reduces the inflammation. The itching gets better. The skin may look better. Naturally, the patient and the doctor think the drug is working. Why would they think otherwise?

But we allege that in some patients the problem was CTCL all along, or that CTCL was beginning to develop. Their argument is that Dupixent can improve some of the outward symptoms while the lymphoma itself continues to progress. So you can have this strange situation where the treatment appears to be succeeding at almost exactly the same time that the underlying disease is becoming more serious.

Eventually something does not fit. The rash keeps returning, it changes, new symptoms develop, or another biopsy finally shows CTCL. By then, months or sometimes years may have passed. That delay matters because CTCL is generally a very different problem when it is diagnosed after it has progressed than when doctors catch it early.

What the Lawsuits Allege

Plaintiffs are making serious allegations against Regeneron and Sanofi. These cases are built primarily on failure-to-warn claims, supported by growing scientific evidence. The gap between the evidence and the warning is wide.

Core Allegations

Dupixent caused, accelerated, or unmasked T-cell lymphoma, depending on the patient. Plaintiffs allege it triggered CTCL or PTCL in some patients, or accelerated disease progression in patients whose early-stage lymphoma was misdiagnosed as eczema.
The manufacturers knew or should have known about the risk. Plaintiffs cite case reports, adverse event data, peer-reviewed studies, and FDA safety-signal activity.
The U.S. label contains no specific warning about CTCL or PTCL. Plaintiffs allege the prescribing information did not adequately warn about CTCL, PTCL, mycosis fungoides, or Sézary syndrome.
Atopic dermatitis and early CTCL can look nearly identical. Plaintiffs argue doctors needed clearer guidance to rule out lymphoma before prescribing the drug in adult-onset, atypical, or treatment-resistant dermatitis cases.
No adequate stop-and-investigate guidance was provided. Plaintiffs allege the companies failed to tell prescribers what to do when symptoms evolved in a way that did not fit ordinary eczema.
Patients would have made different choices with adequate warnings. This is often prescribed for conditions that can be miserable but are usually not life-threatening. Plaintiffs argue many patients would have pursued additional testing, chosen alternative treatment, or never started the drug if warned.

The bottom line is that plaintiffs allege Regeneron and Sanofi prioritized sales of a blockbuster drug over patient safety, and that the result was unnecessary human suffering in patients whose cancer diagnosis was delayed, missed, or worsened.

No one told these patients that what looked like eczema might actually be something far more dangerous.

Medical Evidence Being Cited in CTCL Claims

Several studies, case series, pharmacovigilance reports, and adverse event analyses are being cited in connection with this litigation. Observational database studies have reported higher rates of CTCL diagnoses among patients treated with dupilumab compared to similar patients who were not exposed to the drug.

Other reports describe patients treated for presumed eczema who initially improved, then experienced disease progression consistent with CTCL. These patterns have been discussed in dermatology journals and conferences, particularly in patients with adult-onset or treatment-resistant dermatitis.

No single study proves causation for every patient. Plaintiffs argue that the collective evidence was strong enough to require clearer warnings, screening guidance, and stop-and-investigate instructions for prescribers.

Why the Warning Matters

These lawsuits are not a push to recall Dupixent from the market. The core claim is that doctors and patients were not told what they needed to know. Failure to warn is the spine of these cases.

A manufacturer that knows or should know that a subset of patients with adult-onset or refractory dermatitis may actually harbor early CTCL has a duty to communicate that risk. The practical content of the warning is not complicated: before starting treatment in adults with atypical clinical courses or biopsy-suspicious lesions, consider lymphoma. If the disease evolves in a way that is not typical for eczema, stop and investigate. Do not keep escalating the dosage while hoping the symptoms settle down.

Design defect is less obvious in a biologic drug case than in a mechanical device case, but plaintiffs may still argue that the risk-management design was defective because it lacked guardrails for a known diagnostic gray zone.

In a world where early mycosis fungoides can masquerade as eczema for years, a safer risk-management approach includes prescriber education, biopsy prompts in adult-onset disease, repeat testing when symptoms evolve atypically, and clear stop rules when the clinical course deviates from eczema norms.

Even a low-probability risk demands clear warning, especially when the cost of silence is a cancer diagnosis.

Dupixent Potential Settlement Amounts

Any dollar figures at this stage are speculative. This is new litigation. The science is still being tested, defendants have not been found liable, there are no bellwether verdicts, and the litigation record that usually drives settlement negotiations is still being built. But victims and families deserve a frame of reference, which is why we are willing to speculate about Dupixent settlement amounts

Civil lawsuits assign a dollar value to suffering. The severity of the cancer, burden of treatment, strength of causation, length of delayed diagnosis, and clarity of the manufacturer’s knowledge will shape outcomes. If the medical record shows that the drug played a role in accelerating or masking a lymphoma diagnosis, and if discovery confirms inadequate warnings, the exposure for defendants becomes significant. If the documentation is thin or the disease course is ambiguous, settlement values decline.

Here are early working ranges that may make sense if plaintiffs succeed on the science, warnings, and causation:

Disease Severity	Common Treatment and Impact	Early Working Estimate
Early-stage CTCL	Skin-directed therapies, topical treatment, light therapy, monitoring, partial remission, ongoing surveillance.	$100,000 to $300,000
Moderate disease	Photopheresis, interferon, systemic agents, relapsing disease, work disruption, family impact, ongoing morbidity.	$300,000 to $500,000
Advanced CTCL	Chemotherapy, stem cell transplant consideration, hospitalization, severe quality-of-life decline, economic loss, shortened survival risk.	$500,000 to $1.5 million

Again, this is not some look into a crystal ball. This is just our estimate of how things might play out if these claims are successful.

Also, these figures are not verdict predictions. In a successful trial involving advanced lymphoma, delayed diagnosis, chemotherapy, stem cell transplant, or death, a jury verdict is likely to be much higher. But there are no bellwether verdicts yet, and any settlement range today remains a working estimate at best.

Evidence That Can Support a Dupixent Claim

These cases are record-driven. The strongest Dupixent cases will have a clear timeline showing the skin condition before treatment, the reason the drug was prescribed, what happened during treatment, when symptoms changed, when lymph nodes appeared, when biopsies were done, and when lymphoma was diagnosed.

Record	Why It Matters	What It Can Show
Dermatology records	They show the original diagnosis, symptoms, and reason the drug was prescribed.	Adult-onset dermatitis, treatment-resistant disease, atypical rash, and missed warning signs.
Prescription history	The timing of doses is central to causation.	Start date, number of injections, interruptions, and treatment duration.
Biopsy and pathology reports	These records confirm the diagnosis and may show evolving disease.	Mycosis fungoides, Sézary syndrome, CTCL, PTCL, T-cell clonality, or inconclusive earlier biopsies.
Oncology records	They show disease stage, treatment burden, prognosis, and damages.	Chemotherapy, radiation, photopheresis, transplant evaluation, hospitalizations, and survival risk.
Symptom timeline	The before-and-after story often drives the case.	Initial improvement, worsening rash, lymph nodes, systemic symptoms, and delayed diagnosis.

If the diagnosis is uncertain, an independent pathology review may be important. Some of these cases will turn on whether earlier biopsies should have raised concern for lymphoma before treatment was started or continued.

Latest News and Updates

September, 2026

In a new class action lawsuit, two Dupixent users sued Regeneron, Sanofi-Aventis and Genzyme, alleging the companies failed to warn that Dupixent can cause or accelerate cutaneous T-cell lymphoma.

This is different from the personal injury lawsuits. Neither woman alleges that she currently has CTCL. Instead, they claim Dupixent exposure caused subcellular injury and increased their risk of developing the cancer.

It is primarily a medical monitoring class action for people who used Dupixent but have not developed CTCL. Rather than seeking damages for an existing cancer diagnosis, the plaintiffs argue that their increased risk of CTCL creates a present need for ongoing medical testing. That distinction could make this an important new branch of the Dupixent litigation if similar claims follow.

Our lawyers focus exclusively on individual claims on behalf of victims with CTCL.

August 2026

The Dupixent MDL has moved into its first case-management phase. The parties were required to meet by July 24 to identify areas of agreement and begin preparing for the initial management conference scheduled for October 1. A joint report due September 10 will address plaintiff leadership, discovery, scheduling, future conferences, and the basic structure of the litigation. This is still in its early stages, but these decisions will determine how quickly plaintiffs can obtain internal company records and begin developing the scientific and warning evidence at the center of the CTCL lawsuits.

June 2026

The JPML created the Dupixent MDL in the District of New Jersey. The centralized litigation focuses on CTCL claims. The Panel noted that future expansion to other T-cell lymphomas can be handled through the conditional transfer process.

April 2026

Newly filed complaints continued to allege that the drug either caused, accelerated, or unmasked T-cell lymphoma after treatment for presumed eczema. Several complaints described adult-onset eczema, a short course of injections, swollen lymph nodes, rapid diagnosis of lymphoma, chemotherapy, and stem cell transplant evaluation.

March 2026

Regeneron and Sanofi agreed that federal Dupixent cases should be centralized, although they sought a different venue than plaintiffs. The key fight shifted from whether there should be coordinated litigation to where it should be located and how broad the MDL should be.

February 2026

The MDL proceeding was filed with the JPML as MDL No. 3180. Around the same period, the drug continued to expand commercially and regulatorily with additional FDA-approved uses, while plaintiffs pointed out that the U.S. label still did not contain a specific CTCL warning.

Frequently Asked Questions

Is there a class action lawsuit?

Not really. The federal cases are centralized in an MDL, not a class action. Each plaintiff keeps an individual lawsuit with individual injuries, medical history, damages, and settlement value. This is a better path for plaintiffs than a class action lawsuit, especially if you have a strong claim because you do not want to be lumped into a lot of less serious cases.

What injuries are these lawsuits focused on?

The Dupixent lawsuits are focused on CTCL and related T-cell lymphoma diagnoses after treatment, including mycosis fungoides, Sézary syndrome, and potentially other T-cell lymphoma subtypes depending on the facts and future MDL rulings.

Does the drug cause CTCL?

That is the disputed scientific question in the Dupixent litigation. Plaintiffs allege that it can cause, accelerate, or unmask CTCL in some patients, and that defendants failed to warn about that risk. Defendants are expected to dispute causation and argue that CTCL can already mimic eczema before the drug is ever prescribed.

What makes a lawsuit stronger?

Strong cases often involve adult-onset dermatitis, atypical or treatment-resistant symptoms, drug use before diagnosis, initial improvement followed by worsening, swollen lymph nodes, delayed lymphoma diagnosis, serious treatment, and pathology confirming CTCL or another T-cell lymphoma.

Are there settlement amounts yet?

No. Our lawyers are usually quick to estimate what we think a settlement might be, but it is just too early for that. Case value will depend on the diagnosis, severity, treatment, proof of causation, warning evidence, state law, and, most importantly, whether plaintiffs succeed on the science.

What records should I gather before calling a lawyer?

Save your prescription records, dermatology records, biopsy reports, pathology reports, oncology records, treatment records, photographs of skin changes, pharmacy records, and a timeline of when symptoms began, improved, worsened, and when lymphoma was diagnosed.

What Should You Do Next?

If you or someone you love developed cutaneous T-cell lymphoma after taking Dupixent, get the case evaluated by a lawyer who understands both the medicine and the litigation. These are not routine drug cases. They involve nuanced clinical histories, immunologic complexity, pathology, and an evolving body of science.

The earlier your records are reviewed, the stronger the foundation becomes, especially in cases where the biopsy history is limited or the initial diagnosis was eczema that never responded the way it should have. A lawyer experienced in drug litigation can help secure the complete medical file, obtain an independent pathology review if necessary, and establish a clear timeline that courts and juries can follow.

If a claim is viable, the next step is to preserve your rights under your state’s statute of limitations. That deadline varies, but it often starts running from the time of diagnosis or from the point when a reasonable person should have connected the diagnosis to the drug. The rule depends on the state, but either way, the clock is something you need to worry about.

These cases are unlikely to resolve quickly. But if the science continues to strengthen and the filings continue to build, there is a path to accountability. That path starts with a diagnosis, a timeline, and a decision to act.

Contact Us About Your Claim

If you were diagnosed with CTCL, mycosis fungoides, Sézary syndrome, PTCL, or another T-cell lymphoma after taking Dupixent, our lawyers can review your case for free.

Call us today at 800-553-8082 or request a free online consultation.